PAM
STLN

Panagora Asset Management’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Panagora Asset Management’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-126,985
Closed -$443K – 1258
2025
Q3 		$443K Hold
126,985
– – ﹤0.01% 835
2025
Q2 		$260K Buy
+126,985
New +$317K ﹤0.01% 976
2020
Q4 		– Sell
-5,052
Closed -$52K – 2942
2020
Q3 		$52K Buy
+5,052
New +$52.5K ﹤0.01% 2006

Other funds holding STLN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Panagora Asset Management's STLN Position: Q4 2025 in Review

Panagora Asset Management sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q4 2025, closing a stake of 126,985 shares — an estimated $443K sold.

Panagora Asset Management first reported a position in STLN in Q3 2020 and held it in 3 quarters. The position peaked at $443K in Q3 2025. 117 funds tracked by Wall St. Rank hold STLN as of Q4 2025.

  • Panagora Asset Management reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q4 2025 after selling out during the quarter.
  • Panagora Asset Management sold 126,985 Starling Oncology Institute, Inc. Common Stock shares in Q4 2025, an estimated $443K.
  • Panagora Asset Management first reported a position in Starling Oncology Institute, Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • Panagora Asset Management's Starling Oncology Institute, Inc. Common Stock position peaked at $443K in Q3 2025.
  • 117 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q4 2025.

Based on Panagora Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.